Scisparc Ltd (SPRC)

$4.75 -0.87 (-15.48%)
Market Cap 2.54M
Revenue (ttm) 1.31M
Net Income (ttm) -6.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -479.39%
Debt to Equity Ratio 0.04
Volume 467,600
Avg Vol 5,899,062
Day's Range N/A - N/A
Shares Out 535,000.00
Stochastic %K 19%
Beta 1.15
Analysts Strong Buy
Price Target $20.00

Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. It also sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufac...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 334 47180
Address:
Tower A, 2nd Floor 20 Raul Wallenberg Street, Tel Aviv, Israel
Crazy_Gambler
Crazy_Gambler Oct. 3 at 8:19 PM
$SPRC ALERT SHORT SQUEEZE ! This Stock is shorted like hell more than it can cover without a squeeze, and is about to explode. Come take your free money quickly before it flies due to over shorting. $EPSM $ANRO $WORX $GIPR
1 · Reply
Crazy_Gambler
Crazy_Gambler Oct. 3 at 8:17 PM
$SPRC ALERT SHORT SQUEEZE ! This ticker has been overly shorted and is about to explode. Come take your free money quickly before it flies due to over shorting. $FEMY $ASNS $DFLI $BNAI
1 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:25 PM
$SPRC $PTHS $HSDT $APG Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!
0 · Reply
MovingFast77
MovingFast77 Oct. 3 at 7:14 PM
$SPRC BUYING 2000 SHARES RIGHT NOW #LOWFLOAT MOVES FAST #SHORTSQUEEZE EASY 100% GAIN AT THIS PRICE POTENTIALLY 400%
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 4:15 PM
$SPRC $NITO $WOLF $BQ Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
Flybeast
Flybeast Oct. 3 at 3:47 PM
$SPRC looks good until its not ,we wait out the daily chart
0 · Reply
biscko11
biscko11 Oct. 3 at 3:23 PM
$SPRC what are these stupid Israelis doing? Release the news good or bad already.
0 · Reply
Chinna11
Chinna11 Oct. 3 at 3:22 PM
$SPRC This thing is a scam fuk all with the news and all !
0 · Reply
PoorOffTrading
PoorOffTrading Oct. 3 at 3:15 PM
$SPRC @JamilB91 Dude come short this shit. It’s been red for the past 4 days. Could make a fortune here.
0 · Reply
ItTakesItAll
ItTakesItAll Oct. 3 at 2:29 PM
Remarkable week: 1/2 $DFLI 760%+ .19-1.34 $TBH 475%+ .5555-3.21 $SPRC 355%+ 2.34-8.90 $RVYL 100%+ .299-.62 $IBG 100%+ 2.66-5.38 CRE 50%+ .85-1.30 HCTI 45%+ 2.48-3.72 TNMG 40%+ .2949-.4183 MASK 35%+ .68-.95 RDHL 30%+ 2.51-3.36 SEED 25%+ 1.30-1.67 KAVL 20%+ .56-.68 AIHS 20%+ 2.44-3.0
2 · Reply
Latest News on SPRC
SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Sep 29, 2025, 4:03 PM EDT - 5 days ago

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

SciSparc Stock Surges As It Launches Initiative To Advance Drug Discovery With Quantum Algorithms

Sep 25, 2025, 1:06 PM EDT - 9 days ago

SciSparc Stock Surges As It Launches Initiative To Advance Drug Discovery With Quantum Algorithms

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

Sep 25, 2025, 7:05 AM EDT - 9 days ago

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

Aug 28, 2025, 9:24 AM EDT - 5 weeks ago

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

Aug 28, 2025, 6:45 AM EDT - 5 weeks ago

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Aug 7, 2025, 7:32 AM EDT - 2 months ago

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

Jul 30, 2025, 4:34 PM EDT - 2 months ago

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Jul 30, 2025, 8:12 AM EDT - 2 months ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

Jul 22, 2025, 7:32 AM EDT - 2 months ago

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

SciSparc Announces 1-for-21 Reverse Share Split

Jun 24, 2025, 5:03 PM EDT - 3 months ago

SciSparc Announces 1-for-21 Reverse Share Split

SciSparc Announces Publication of Japanese Patent Application

May 27, 2025, 7:32 AM EDT - 4 months ago

SciSparc Announces Publication of Japanese Patent Application

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Apr 25, 2025, 7:59 AM EDT - 5 months ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

CMND

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

Mar 3, 2025, 8:25 AM EST - 7 months ago

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

Feb 27, 2025, 8:45 AM EST - 7 months ago

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

Feb 18, 2025, 7:17 AM EST - 8 months ago

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

Feb 4, 2025, 9:00 AM EST - 8 months ago

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Jan 15, 2025, 7:34 AM EST - 9 months ago

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

Jan 13, 2025, 8:41 AM EST - 9 months ago

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Jan 7, 2025, 7:25 AM EST - 9 months ago

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

Jan 6, 2025, 11:04 AM EST - 9 months ago

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Jan 6, 2025, 7:50 AM EST - 9 months ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

Dec 31, 2024, 9:24 AM EST - 9 months ago

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

S&P 500 Edges Lower, SciSparc Shares Surge

Dec 26, 2024, 2:36 PM EST - 10 months ago

S&P 500 Edges Lower, SciSparc Shares Surge

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

Dec 26, 2024, 6:46 AM EST - 10 months ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

Dec 16, 2024, 7:40 AM EST - 10 months ago

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

Sep 30, 2024, 9:25 AM EDT - 1 year ago

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

Sep 26, 2024, 9:05 AM EDT - 1 year ago

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 23, 2024, 8:17 AM EDT - 1 year ago

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 18, 2024, 4:09 PM EDT - 1 year ago

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

Sep 16, 2024, 4:06 PM EDT - 1 year ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer

Sep 11, 2024, 7:40 AM EDT - 1 year ago

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Sep 6, 2024, 7:55 AM EDT - 1 year ago

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

Aug 29, 2024, 4:25 PM EDT - 1 year ago

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

Aug 28, 2024, 8:55 AM EDT - 1 year ago

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

Aug 23, 2024, 4:09 PM EDT - 1 year ago

SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

Aug 22, 2024, 8:12 AM EDT - 1 year ago

SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment

Aug 19, 2024, 4:11 PM EDT - 1 year ago

SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment

Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy

Aug 19, 2024, 7:51 AM EDT - 1 year ago

Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy

SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million

Aug 16, 2024, 4:30 PM EDT - 1 year ago

SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million

SciSparc Updates Regarding the Status of the AutoMax Merger

Aug 14, 2024, 4:53 PM EDT - 1 year ago

SciSparc Updates Regarding the Status of the AutoMax Merger

SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

Aug 6, 2024, 8:57 AM EDT - 1 year ago

SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer

Jul 22, 2024, 8:20 AM EDT - 1 year ago

SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

Jul 17, 2024, 7:07 AM EDT - 1 year ago

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

Jul 16, 2024, 11:55 AM EDT - 1 year ago

SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

Jul 16, 2024, 6:03 AM EDT - 1 year ago

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company

Jul 8, 2024, 8:30 AM EDT - 1 year ago

SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company

SciSparc Secures Strategic Advantage with Grant of European Patent

May 31, 2024, 7:17 AM EDT - 1 year ago

SciSparc Secures Strategic Advantage with Grant of European Patent

Action Alliance Research: Family, Friends Need More Resources and Support to Help Loved Ones Who Are Struggling with Their Mental Health

May 21, 2024, 9:26 AM EDT - 1 year ago

Action Alliance Research: Family, Friends Need More Resources and Support to Help Loved Ones Who Are Struggling with Their Mental Health

SciSparc to Acquire AutoMax

Apr 11, 2024, 8:15 AM EDT - 1 year ago

SciSparc to Acquire AutoMax

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

Mar 27, 2024, 8:55 AM EDT - 1 year ago

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

Crazy_Gambler
Crazy_Gambler Oct. 3 at 8:19 PM
$SPRC ALERT SHORT SQUEEZE ! This Stock is shorted like hell more than it can cover without a squeeze, and is about to explode. Come take your free money quickly before it flies due to over shorting. $EPSM $ANRO $WORX $GIPR
1 · Reply
Crazy_Gambler
Crazy_Gambler Oct. 3 at 8:17 PM
$SPRC ALERT SHORT SQUEEZE ! This ticker has been overly shorted and is about to explode. Come take your free money quickly before it flies due to over shorting. $FEMY $ASNS $DFLI $BNAI
1 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:25 PM
$SPRC $PTHS $HSDT $APG Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!
0 · Reply
MovingFast77
MovingFast77 Oct. 3 at 7:14 PM
$SPRC BUYING 2000 SHARES RIGHT NOW #LOWFLOAT MOVES FAST #SHORTSQUEEZE EASY 100% GAIN AT THIS PRICE POTENTIALLY 400%
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 4:15 PM
$SPRC $NITO $WOLF $BQ Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
Flybeast
Flybeast Oct. 3 at 3:47 PM
$SPRC looks good until its not ,we wait out the daily chart
0 · Reply
biscko11
biscko11 Oct. 3 at 3:23 PM
$SPRC what are these stupid Israelis doing? Release the news good or bad already.
0 · Reply
Chinna11
Chinna11 Oct. 3 at 3:22 PM
$SPRC This thing is a scam fuk all with the news and all !
0 · Reply
PoorOffTrading
PoorOffTrading Oct. 3 at 3:15 PM
$SPRC @JamilB91 Dude come short this shit. It’s been red for the past 4 days. Could make a fortune here.
0 · Reply
ItTakesItAll
ItTakesItAll Oct. 3 at 2:29 PM
Remarkable week: 1/2 $DFLI 760%+ .19-1.34 $TBH 475%+ .5555-3.21 $SPRC 355%+ 2.34-8.90 $RVYL 100%+ .299-.62 $IBG 100%+ 2.66-5.38 CRE 50%+ .85-1.30 HCTI 45%+ 2.48-3.72 TNMG 40%+ .2949-.4183 MASK 35%+ .68-.95 RDHL 30%+ 2.51-3.36 SEED 25%+ 1.30-1.67 KAVL 20%+ .56-.68 AIHS 20%+ 2.44-3.0
2 · Reply
AtlasFrontier
AtlasFrontier Oct. 3 at 3:45 AM
I found a stock that is about to absolutely explode Tomorrow. Check out GIPR 🚨🚀 GIPR 🚀🔥 🔹 Early lease extension w/ Best Buy thru 2032 + rent bump 6.5% 📈 🔹 Revenue up ~28% YoY to $9.7M 💰 🔹 Exploring strategic alternatives – sale/merger/recap possibilities 🧐 🔹 High occupancy & investment-grade tenants keep cash flowing 🏢 $POET $MGIH $KULR $SPRC
0 · Reply
MajorStockTradingLLC
MajorStockTradingLLC Oct. 3 at 12:47 AM
$SPRC in will sell at 7.00 come to me big boy.
0 · Reply
MoonCowBoy
MoonCowBoy Oct. 3 at 12:24 AM
$HSDT $WBX $SPRC $PTHS *
2 · Reply
Doqflet
Doqflet Oct. 2 at 7:38 PM
$SPRC SHORT -RUN AWAY...
0 · Reply
Doqflet
Doqflet Oct. 2 at 7:36 PM
$SPRC Moving UP Slowly >>>>>>BOOOOM
1 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:31 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $BIVI $WBX $SPRC $PTHS .
0 · Reply
MileHighAC92
MileHighAC92 Oct. 2 at 5:39 PM
$NITO $TTNP I notice the BTTC news last night. I forgot about it this morning and missed it. I’m in position with NITO in case it has a good run with the acquisition news. $SPRC
0 · Reply
crookedtomlee
crookedtomlee Oct. 2 at 5:00 PM
$SPRC $NITO
0 · Reply
Kzixo
Kzixo Oct. 2 at 4:55 PM
$SPRC I still believe this will have a crazy squeeze
0 · Reply
VikingsTrades
VikingsTrades Oct. 2 at 4:18 PM
$SPRC NITO is starting to run because of the merger
0 · Reply
Chinna11
Chinna11 Oct. 2 at 3:00 PM
$SPRC why the big drop today ?
1 · Reply
biscko11
biscko11 Oct. 2 at 2:59 PM
$SPRC the merger news was delayed for Tom Kippur Evening of Wed, Oct 1, 2025 – Thu, Oct 2, 2025. the courts were closed. Friday or Monday we ride.
1 · Reply